Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension
NCT03860220Phase 4Completed
- Start
- Apr 2019
- Primary completion
- Sep 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of telmisartan + amlodipine + rosuvastatin in hypertension (HTN) and dyslipidemia (2 arms). Primary endpoints: Mean Sitting Systolic Blood Pressure at 8 weeks and Low-Density Lipoprotein Cholesterol at 8 weeks. Started Apr 2019; status: completed.
02
Drugs
telmisartan + amlodipine + rosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03860220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860220.